TrialJournal of neuro-oncology2016

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.

Mustafa Khasraw et al.PubMed ↗Publisher ↗

No numbers read from the abstract.